# Transient Hyperglycemia in a Patient With Type 2 Diabetes After COVID-19 Messenger RNA Vaccination: A Case Report

**Authors:** Aniebietabasi Okon-Umoren, Sean Yaphe, Andrea Smith, Karla D Passalacqua, Katarzyna Budzynska

PMC · DOI: 10.7759/cureus.63983 · Cureus · 2024-07-06

## TL;DR

A 76-year-old man with type 2 diabetes experienced a sudden rise in blood sugar after receiving a COVID-19 mRNA vaccine, which improved with insulin and a new medication.

## Contribution

This case report highlights a potential link between the new mRNA vaccines and transient hyperglycemia in patients with diabetes.

## Key findings

- A patient with well-controlled type 2 diabetes experienced significant hyperglycemia after receiving a COVID-19 mRNA vaccine.
- The patient's glucose levels improved after treatment with insulin and a glucagon-like peptide-1 agonist.
- The case suggests a possible, though not yet proven, connection between mRNA vaccines and blood sugar changes in diabetic patients.

## Abstract

The development of new vaccines against the SARS-CoV-2 virus in response to the COVID-19 pandemic represents a milestone in the history of public health. However, due to the rapid development and short duration of these new vaccines, the full spectrum of side effects is not yet known. A 76-year-old man presented to the clinic for follow-up after being discharged from the emergency department for hyperglycemia. His medical history included well-controlled type 2 diabetes for two years, hypertension, and hyperlipidemia. He had recently noticed high home blood glucose readings over 400 mg/dL, and his hemoglobin A1c (mean 90-day glucose level) had increased from 6.5% to 12.6%. Notably, the patient reported having excellent health behaviors, including daily exercise, a closely monitored healthy diet, and regular blood glucose testing. After extensive endocrinology workup, the rapid change in blood glucose was thought to be due to his having recently received the COVID-19 messenger RNA (mRNA) vaccine. He was started on long- and short-acting insulin and a glucagon-like peptide-1 agonist (novel injectable type 2 diabetes medication), with improvement in blood glucose. He was tapered off all medications and remains on metformin 1,000 mg twice daily after one year.Whether the new COVID-19 mRNA vaccines directly incur hyperglycemia within certain groups of patients with diabetes is not known; thus, studies exploring the relationship between vaccine antigen binding and pancreatic function are needed.

## Linked entities

- **Diseases:** type 2 diabetes (MONDO:0005148), hyperglycemia (MONDO:0002909), hyperlipidemia (MONDO:0021187)

## Full-text entities

- **Diseases:** diabetes (MESH:D003920), hypertension (MESH:D006973), COVID-19 (MESH:D000086382), hyperlipidemia (MESH:D006949), Hyperglycemia (MESH:D006943), Type 2 Diabetes (MESH:D003924)
- **Chemicals:** glucose (MESH:D005947), insulin (MESH:D007328), metformin (MESH:D008687), blood glucose (MESH:D001786)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11299958/full.md

## References

16 references — full list in the complete paper: https://tomesphere.com/paper/PMC11299958/full.md

---
Source: https://tomesphere.com/paper/PMC11299958